Welcome to our dedicated page for Scientific Ind SEC filings (Ticker: SCND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scientific Industries, Inc. (SCND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Scientific Industries is a life science tool provider and manufacturer of DOTS bioprocessing systems, VIVID vision-based pill counters, and Torbal weighing products, and its filings offer detailed insight into how these operations are reflected in its financial statements and governance.
Investors can review periodic reports such as Forms 10-K and 10-Q, which include audited and unaudited financial statements, segment information for Benchtop Laboratory Equipment Operations and Bioprocessing Systems Operations, and management’s discussion of factors affecting revenues and margins. For example, the company’s communications reference trends in Torbal Division sales, Bioprocessing Systems revenue softness, and the effects of tariffs and customer budgets, topics that are typically expanded upon in its quarterly and annual reports.
This page also surfaces current reports on Form 8-K, including the 8-K/A describing the Asset Purchase Agreement under which Scientific Industries sold substantially all assets of its Genie Division to Troemner, LLC. Such filings outline material definitive agreements, completion of asset sales, and related pro forma financial information. Notifications of late filing, such as the NT 10-Q for the quarter ended September 30, 2025, are also part of the company’s SEC record and explain timing of certain reports.
In addition, users can access proxy materials like the Definitive Proxy Statement on Schedule 14A, which covers matters for shareholder votes, including director elections, amendments to equity incentive plans, and ratification of the independent registered public accounting firm. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important disclosures about Scientific Industries’ capital structure, governance, and strategic transactions while retaining the ability to consult the full original filings.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options covering 130,000 shares of common stock on February 17, 2026. The options have an exercise price of $0.60 per share, were granted at no purchase cost, and vest on a 4 year cliff from the grant date. Following this award, Santos holds options on a total of 563,388 shares directly. This is a compensation-related grant rather than an open-market share purchase or sale.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options to acquire 50,000 shares of common stock. The options carry an exercise price of $0.60 per share, become exercisable starting on February 17, 2027, and expire on February 17, 2036. According to the disclosure, these options were granted in lieu of salary and vest over one year at a rate of 1/12th per month. After this grant, Santos directly holds 433,388 derivative securities related to the company.
Scientific Industries, Inc. reported full-year 2025 results, highlighted by the sale of its Genie benchtop product line and continued investment in bioprocessing. Net revenues rose to $5,053,800, driven mainly by Torbal weighing products, while dependence on a single pill-counter customer remained high.
The company posted a net loss of $1,220,400, a substantial improvement from 2024 as it recorded a $5,263,400 gain on the Genie sale and reduced general, selling, and R&D expenses. However, gross margin fell to 25.8% due to bioprocessing inventory write-offs.
Cash and equivalents were $955,000 at year-end, with an accumulated deficit of $35,150,900. Management expects existing cash plus proceeds and earn-outs from the Genie transaction to fund operations for at least one year while it pursues growth in its Bioprocessing Systems segment.
SCIENTIFIC INDUSTRIES INC Chairman John A. Moore bought additional shares of the company’s stock. On this Form 4, he reports an open-market purchase of 9,000 shares of Common Stock at a price of $0.58 per share on March 23, 2026.
Following this transaction, Moore directly owns 926,871 shares of Scientific Industries common stock. This filing reflects a net increase in his holdings, as there were no reported sales, option exercises, or derivative transactions in this disclosure.
Scientific Industries Inc. reported a stock option grant to its Chief Financial Officer, Zachary Rovinsky. He received options for 25,000 shares of common stock at an exercise price of $0.6000 per share. These options vest on a 4-year cliff from the grant date, meaning none vest until the four-year mark, when they vest in full.
After this award, he holds a total of 45,000 stock options directly. This is a compensation-related, non-market transaction rather than an open-market purchase or sale of common shares.
Scientific Industries Inc. director Michael Blechman received grants of stock options covering a total of 44,000 shares of common stock on February 17, 2026. The awards consist of 24,000 and 20,000 option shares, each with an exercise price of 0.6000 and expiration on February 17, 2036.
The options were granted in lieu of cash director fees and vest over one year at 1/12 per month, providing compensation rather than reflecting open-market buying. Following these grants, Blechman directly holds 116,186 stock options linked to the company’s common stock.
SCIENTIFIC INDUSTRIES INC Chairman of the Board and director John A. Moore made an open-market purchase of the company’s common stock. He bought 1,000 shares on February 19, 2026 at a price of $0.65 per share. Following this transaction, Moore directly owns 917,871 common shares of Scientific Industries.
Scientific Industries Inc. director and chairman John A. Moore received stock option awards as compensation. He was granted stock options covering 230,000 shares of common stock and an additional 30,000-share option, each with a conversion price of $0.6000 per share.
The filing shows these awards were granted in lieu of cash compensation and vest over one year at a rate of 1/12 per month. Following these grants, Moore holds stock options covering 916,871 shares, giving him additional long-term equity exposure but reflecting routine, compensation-related awards rather than open-market purchases.
Scientific Industries Inc. director John J. Nicols received stock options as compensation instead of cash fees. On February 17, 2026, he was granted stock options covering a total of 140,000 shares of Common Stock, with an exercise price of $0.60 per share and an expiration date of February 17, 2036.
The options vest over one year at a rate of 1/12 per month. Following these awards, Nicols holds 275,778 stock options in total, reflecting routine equity-based director compensation rather than open‑market trading.
Scientific Industries, Inc. reported a change in its independent auditor following an acquisition within the accounting industry. Effective January 14, 2026, the company’s Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP (BPB) and approved Carr, Riggs & Ingram, LLC (CRI) as the new independent registered public accounting firm, after CRI acquired certain assets related to BPB’s capital markets practice on January 1, 2026.
BPB had been engaged from August 22, 2025 through December 31, 2025 but issued no audit or review reports during that period. The company states there were no disagreements with BPB on accounting principles, financial statement disclosure, or auditing scope or procedures, and no reportable events under Regulation S‑K during the engagement. The company also states it did not consult with CRI on accounting or auditing matters before the appointment. BPB’s confirming letter to the SEC is filed as an exhibit.